Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer-Reference-Cited by-同舟云学术

Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer

Published:2020-07 Issue:1 Volume:159 Page:306-319.e12
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Ma Ying^ORCID,Li Jun,Wang Huamin,Chiu Yulun,Kingsley Charles V.,Fry David,Delaney Samantha N.,Wei Spencer C.,Zhang Jianhua,Maitra Anirban^ORCID,Yee Cassian

Funder

Parker Institute for Cancer Immunotherapy

National Cancer Institute

Hirshberg Foundation for Pancreatic Cancer Research

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference29 articles.

1. Cancer immunotherapy using checkpoint blockade;Ribas;Science,2018

2. Genetics and biology of pancreatic ductal adenocarcinoma;Ying;Genes Dev,2016

3. Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment;Katlinski;Cancer Cell,2017

4. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer;Feig;Proc Natl Acad Sci U S A,2013

5. Dynamics of the immune reaction to pancreatic cancer from inception to invasion;Clark;Cancer Res,2007

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Divergent response to radio-immunotherapy is defined by intrinsic features of the tumor microenvironment;2024-09-10

2. Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders;Advanced Science;2024-09-09

3. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy;Journal of Translational Medicine;2024-08-09

4. The Pivotal Role of Preclinical Animal Models in Anti-Cancer Drug Discovery and Personalized Cancer Therapy Strategies;Pharmaceuticals;2024-08-09

5. A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: Fecal microbiota transplantation;Critical Reviews in Oncology/Hematology;2024-08